This technology includes a new class of synthetic peptides that activate Lipoprotein Lipase (LPL), a key plasma enzyme that lowers triglycerides. Mutations in apoC-II is a genetic cause of severe hypertriglyceridemia, which can lead to cardiovascular disease and pancreatitis. The last helical domain (3rd helix) of apoC-ll activates LPL, and we discovered by making a series of amino acids substitutions in the second helix to increase its ability to bind to lipoproteins that we were able to produce novel apoC-II mimetic peptides that potently activate LPL and are less likely to be immunogenic.